{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.80","upperLimit":"8.62","value":"6.85"},{"comment":"insufficient number of participants with events","groupId":"OG001","lowerLimit":"5.00","upperLimit":"NA","value":"7.6"},{"comment":"insufficient number of participants with events","groupId":"OG002","lowerLimit":"3.00","upperLimit":"NA","value":"7.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"description":"From the time from enrollment until the time of death from any cause or last follow-up. Patients will be followed clinically as outlined in the treatment schedule and will be followed off study for death.","dispersionType":"95% Confidence Interval","groups":[{"description":"4mg RRx-001 once weekly (QW) until progression, followed by up to 6 cycles of platinum doublet chemotherapy","id":"OG000","title":"RRx-001 + Platinum Doublet (A01-09)"},{"description":"RRx-001 weekly for 3 weeks followed by up to 6 cycles of platinum doublet chemotherapy and then RRx-001 maintenance (for patients with stable disease (SD) or better at discontinuation of platinum).","id":"OG001","title":"RRx-001 + Platinum + RRx-001 (A10)"},{"description":"Standard of Care Investigator's Choice Control Arm, treatment options of one of the following: carboplatin, etoposide, doxil, gemcitabine, vinorelbine or taxane treatments until progression or intolerable toxicity","id":"OG002","title":"Investigator's Choice (A10)"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"From start of treatment through death for up to 64 months from Start of Treatment.","title":"Overall Survival","type":"PRIMARY","unitOfMeasure":"Months"}